Cost-effective solutions
for large chemical space exploration

Accelerate your drug discovery process and reduce costs

Besides the upfront investments in infrastructure, one of the major barriers to access and exploit ultra High Throughput Screening (uHTS) of large compound libraries for academic centres, start-ups, and biotech companies active in drug discovery research, is the inherent high cost of reagents and consumables. Miniaturisation is key to reduce time and costs during the screening campaigns of large compound libraries and receive your high-quality hit lists. Whether you already have an assay in place in 96- or 384-well plate format or you want us to do the assay development for your target from scratch, we can miniaturise them to 1536-well format for screening purposes.

During assay development, optimization and miniaturisation, several experiments are performed for each project to check for appropriate assay component concentrations, stability of reagents and their minimal required concentrations or volumes, kinetics (such as incubation time, temperature, Km/Kd determination), assay linearity, EC50/IC50 of reference compounds, inter-/intraplate variation, DMSO tolerance, optimal final reagent concentrations and volume per well required, plate effects as well as robustness of the assay using reagents, chemicals, and microtiter plates from different vendors. For this, several factors beyond and above assay robustness and window were taken into consideration, such as the choice of appropriate protein (state) and biochemically sound assay composition including concentrations of assay components, types of salts, pH, reducing agents, detergents, primary assay pitfalls, and so forth.

Your Assay tailor-made for ultra High Throughput screening by means of miniaturisation

We have a solid track record in miniaturising challenging biochemical, cellular and biophysical assays to 384- and 1536-well formats for medium to ultra High Throughput Screening. The reduction in final reagent volumes and number of consumables such as assay plates has a major impact on reducing the cost of lead discovery campaigns. This makes the miniaturisation of a screening assay an essential step in your drug discovery process. By means of miniaturisation, we are able to reduce sample volumes and screen more compounds per plate, saving amounts of compounds, reagents and time used, while maintaining reliability, robustness, and reproducibility.

The experienced team at Pivot Park Screening Centre finds the right balance between saving time and costs on one hand and producing reliable, reproducible and quantitative results on the other. We can develop a feasible biological assay from your concept, and optimize and miniaturise to a 1536-well format for screening purposes.

Speed up your drug discovery screen

Pivot Park Screening Centre operates at the intersection of biology, chemistry and automation.
Ultra High Throughput Screening (uHTS) assays require accurate and reliable liquid handling and flexible automation. That is why Pivot Park Screening Centre has a wide range of automated systems like robust liquid handling instruments, accurate dispensers, plate washers, readout equipment, etc., to support miniaturisation of challenging biochemical and cellular assays.

Miniaturised assays

Thank you for you interest!

To download this publication we would like to receive your e-mail. 

Thank you for you interest!

To download this publication we would like to receive your e-mail.